Thyroid cancer, RET-positive

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Note: these are regimens tested in biomarker-specific populations, please see the main thyroid cancer page for other regimens.

1 regimens on this page
1 variants on this page

Advanced or metastatic disease

Selpercatinib monotherapy

back to top


FDA-recommended dose
Study Years of enrollment Evidence
Wirth et al. 2020 (LIBRETTO-001) 2017-2019 Phase I/II (RT)

Biomarker eligibility criteria

  • RET fusion-positive thyroid cancer
  • RET-mutant medullary thyroid cancer

Targeted therapy

  • Selpercatinib (Retevmo) with or without food, as follows:
    • Less than 50 kg: 120 mg PO twice per day
    • 50 kg or more: 160 mg PO twice per day

Continued indefinitely


  1. LIBRETTO-001: Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O, Weiss J, de la Fouchardière C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J, Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH, Cabanillas ME. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med. 2020 Aug 27;383(9):825-835. link to original article PubMed NCT03157128